This is a pivotal clinical success in a hard-to-treat cancer with high unmet need. The magnitude of survival benefit suggests high likelihood of regulatory approval and commercial adoption. Traders should anticipate significant upward revaluation of RVMDW, especially given the Priority Voucher pathway which enhances commercial incentives.
Price Chart
Executive Summary
Revolution Medicines announced positive topline results from its Phase 3 RASolute 302 trial, showing daraxonrasib significantly improved overall survival and progression-free survival in metastatic pancreatic cancer patients compared to chemotherapy. The company plans to submit the data for regulatory approval, including under a U.S. FDA Priority Voucher.
Key Facts
- Daraxonrasib demonstrated a median overall survival of 13.2 months versus 6.7 months for chemotherapy (hazard ratio 0.40, p < 0.0001) in metastatic pancreatic ductal adenocarcinoma.
- The drug showed statistically significant and clinically meaningful improvements in both progression-free survival and overall survival.
- Daraxonrasib was generally well tolerated with no new safety signals.
- Results are from the first interim analysis and are considered final.
- Company plans to submit data to global regulators, including the FDA, as part of a New Drug Application under a Priority Voucher.
Financial Impact
Potential blockbuster drug approval in a high-mortality indication with no current effective treatments; could transform company prospects and market valuation.
Risk Factors
- Regulatory approval not guaranteed despite strong data
- Potential delays in submission or review timeline
- Future competition in KRAS-targeted therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-152039 |
| Document: 0001193125-26-152039-index-headers.html | 0001193125-26-152039 |
| Document: 0001193125-26-152039-index.html | 0001193125-26-152039 |
| Document: 0001193125-26-152039.txt | 0001193125-26-152039 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Apr 17, 2026 24w ago | 8-K | $1.88 $9.07 | ▼ −382.45% | ▼ −375.67% | — |
Apr 16, 2026 24w ago | 8-K | $1.88 $8.98 | ▲ +377.66% | ▲ +371.52% | — |
Apr 15, 2026 24w ago | 424B5 | $1.88 $8.96 | ▲ +376.60% | ▲ +369.55% | — |
Apr 15, 2026 24w ago | 424B5 | $1.88 $8.96 | ▼ −376.60% | ▼ −369.55% | — |
Apr 15, 2026 24w ago | 144 | $1.88 $8.96 | ▼ −376.60% | ▼ −369.55% | — |
Apr 13, 2026 24w ago | 424B5 | $1.88 $9.82 | ▼ −422.13% | ▼ −413.61% | — |
Apr 13, 2026 24w ago | 424B5 | $1.88 $9.82 | ▼ −422.13% | ▼ −413.61% | — |
Apr 13, 2026 24w ago | 8-K | $1.88 $9.66 | ▲ +413.83% | ▲ +404.91% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access